Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Martínez, C.
Right arrow Articles by Agúndez, J. A.G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Martínez, C.
Right arrow Articles by Agúndez, J. A.G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol. 23, No. 4, 667-668, April 2002
© 2002 Oxford University Press

RESPONSE TO LETTER TO THE EDITOR

Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk

Carmen Martínez1, Elena García-Martín2, José M. Ladero3, Javier Sastre4, Francisco Garcia-Gamito5, Manuel Diaz-Rubio3 and José A.G. Agúndez1,,6

1 Department of Pharmacology, Medical School and
2 Department of Biochemistry, School of Biological Sciences, University of Extremadura, Avda. de Elvas s/n. E-06071, Badajoz, Spain,
3 Service of Gastroenterology and
4 Medical Oncology, San Carlos University Hospital, Prof. Martin Lagos s/n, E-28040, Madrid, Spain and
5 Service of Surgery, Hospital INSALUD, Pol Nueva Ciudad s/n E-06800 Mérida, Spain

Dear Sir,

Thank you for the opportunity to reply the letter from Yasar et al. In their letter, Yasar et al., expressed concerns regarding the selection of the control group in our previous study (1). With regard to the first matter addressed i.e., that patients with benign diseases of the colon are more adequate controls than healthy subjects we do not agree for the following reasons.

From a clinical point of view it has little sense to compare cancer patients with patients with benign diseases. . . . [Full Text of this Article]

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CarcinogenesisHome page
K. Hemminki and A. Forsti
Proper controls for SNP studies?
Carcinogenesis, August 1, 2002; 23(8): 1405 - 1406.
[Full Text] [PDF]